DexCom Inc. Files Q1 2025 10-Q

Ticker: DXCM · Form: 10-Q · Filed: May 1, 2025 · CIK: 1093557

Dexcom INC 10-Q Filing Summary
FieldDetail
CompanyDexcom INC (DXCM)
Form Type10-Q
Filed DateMay 1, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, medical-devices

Related Tickers: DXCM

TL;DR

DexCom's Q1 2025 10-Q is in, showing their latest financial health. **#DXCM**

AI Summary

DexCom Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and balance sheet information are presented, reflecting the company's ongoing activities in the medical device sector.

Why It Matters

This filing provides investors and analysts with the latest financial snapshot of DexCom, a key player in continuous glucose monitoring technology, impacting its stock valuation and future investment decisions.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing with no immediate or unusual risk factors highlighted.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of DexCom Inc.?

DexCom Inc. is primarily involved in the 'Surgical & Medical Instruments & Apparatus' industry, SIC code 3841.

For what period is this 10-Q report filed?

This 10-Q report is for the period ending March 31, 2025.

When was this 10-Q filing submitted to the SEC?

The filing was submitted on May 1, 2025.

What is the company's state of incorporation?

DexCom Inc. is incorporated in Delaware (DE).

Where is DexCom Inc. headquartered?

The company's business and mailing address is in San Diego, California (CA).

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding DEXCOM INC (DXCM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing